# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Scotiabank analyst Sung Ji Nam initiates coverage on Myriad Genetics (NASDAQ:MYGN) with a Sector Outperform rating and annou...
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the addition of a new ...
Jefferies analyst Tycho Peterson assumes Myriad Genetics (NASDAQ:MYGN) with a Underperform rating and lowers Price Target of...
Myriad's Prolaris Test is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiat...
Piper Sandler analyst John Peterson maintains Myriad Genetics (NASDAQ:MYGN) with a Neutral and raises the price target from ...